Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diethylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K2 | P36507 | 8/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 8/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
| ▸ | FLT4 | P35916 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18038517 | 0.92 | MAP2K2 (0.41) | MAP2K2MAP2K1MAPK8HSD17B1IKBKB | |
| Piperidine SCHEMBL3364782 | 0.79 | MAP2K1 (0.34) | MAP2K2MAP2K1MAPK8HSD17B1PARP1 | |
| SCHEMBL361379 | 0.75 | GABRP (0.44) | MAP2K2MAP2K1HSD17B1MEN1ALDH1A1 | |
| Diethylamine SCHEMBL7576781 | 0.75 | MAPT (0.42) | MAPK8MEN1ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL28795337 | 0.75 | ALDH1A1 (0.45) | ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL9511771 | 0.75 | MAP2K2 (0.42) | MAP2K2MAP2K1MAPK8MEN1KMT2A | |
| Diethylamine SCHEMBL8601287 | 0.74 | PARP1 (0.41) | MAPK8MEN1ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL688069 | 0.73 | MAP2K2 (0.46) | MAP2K2MAP2K1MKNK1MKNK2ALDH1A1 | |
| SCHEMBL4009706 | 0.73 | HTR1D (0.44) | MAP2K2MAP2K1KMT2A | |
| SCHEMBL4604668 | 0.72 | PARP1 (0.42) | MAPK8HSD17B1MEN1KMT2APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010006619-A1 | Compounds for cancer imaging and therapy | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2001-07-05 | — | — | US | claimed |
| EP-0821594-A1 | COMPOUNDS FOR CANCER IMAGING AND THERAPY | JOHN, Christy S. (US) | 1998-02-04 | — | — | EP | claimed |
| WO-1996032968-A1 | COMPOUNDS FOR CANCER IMAGING AND THERAPY | JOHN CHRISTY S (US) | 1996-10-24 | — | — | WO | claimed |
| EP-0650372-A4 | COMPOUNDS FOR CANCER IMAGING AND THERAPY. | JOHN CHRISTY S (US) | 1996-07-03 | — | — | EP | claimed |
| EP-0650372-A1 | COMPOUNDS FOR CANCER IMAGING AND THERAPY | JOHN, Christy S. (US) | 1995-05-03 | — | — | EP | claimed |
| WO-1994026314-A1 | COMPOUNDS FOR CANCER IMAGING AND THERAPY | JOHN CHRISTY S (US) | 1994-11-24 | — | — | WO | claimed |
| US-6517811-B2 | Diagnosing a mammal for presence of a tumor by administering compounds such as 125-I-(2-piperidinylaminoethyl)-4-iodobenzamide which have an affinity for cell surface sigma receptors | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2003-02-11 | — | — | US | disclosed |
| US-6447748-B1 | Benzamide compounds for cancer imaging and therapy | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2002-09-10 | — | — | US | disclosed |
| US-20010006619-A1 | Compounds for cancer imaging and therapy | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2001-07-05 | — | — | US | disclosed |
| US-6015543-A | DIAGNOSIS OF TUMORS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2000-01-18 | — | — | US | disclosed |
| US-5993777-A | Benzamide compounds for cancer imaging and therapy | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| US-5911970-A | ANTITUMOR AGENTS AND ANTICARCINOGENIC AGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1999-06-15 | — | — | US | disclosed |
| EP-0821594-A1 | COMPOUNDS FOR CANCER IMAGING AND THERAPY | JOHN, Christy S. (US) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996032968-A1 | COMPOUNDS FOR CANCER IMAGING AND THERAPY | JOHN CHRISTY S (US) | 1996-10-24 | — | — | WO | disclosed |
| EP-0650372-A4 | COMPOUNDS FOR CANCER IMAGING AND THERAPY. | JOHN CHRISTY S (US) | 1996-07-03 | — | — | EP | disclosed |
| EP-0650372-A1 | COMPOUNDS FOR CANCER IMAGING AND THERAPY | JOHN, Christy S. (US) | 1995-05-03 | — | — | EP | disclosed |
| WO-1994026314-A1 | COMPOUNDS FOR CANCER IMAGING AND THERAPY | JOHN CHRISTY S (US) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010006619-A1 | Compounds for cancer imaging and therapy | SIGMAR1, TMEM97, ADRB3 | MAP2K2 2795/4885MAP2K1 3252/4885MAPK8 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.